Canada

Zymeworks

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25

Lead Product(s): ZW25,Docetaxel,Tislelizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

BeiGene has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy for metastatic HER2+ breast cancer.

Sierra Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Attacking drug-resistant tumors with Sierra’s struggling CHK1 blocker

Lead Product(s): SRA737,Momelotinib,Aphidicolin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2020

Details:

Scientists found that combining the drug with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.

IMV

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Clinical Translational Data Supports DPX-Survivac Mechanism of Action

Lead Product(s): DPX-Survivac

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

DPX-Survivac generated survivin-specific T cells in the blood of 80% of patients sampled.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Zymeworks

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25

Sierra Oncology

Attacking drug-resistant tumors with Sierra’s struggling CHK1 blocker

IMV

Clinical Translational Data Supports DPX-Survivac Mechanism of Action